Regenicin, Inc. RGIN Archives

FridayJun 17, 2011 9:43 am

Regenicin, Inc. (RGIN) Repays Loans; Continues to Execute Business Strategy

Regenicin, Inc., a biotechnology company focused on developing regenerative cell therapies to restore the health of damaged tissues and organs, today announced the repayment of short-term secured loans totaling $242,993.54. The company received these short-term loans from supporters of the company, including members of its board of directors, to finance operations. The repayment fully satisfied the terms of the loans, thereby releasing the company's assets that were held as security. The three board members who were reimbursed for their loan contributions were Dr. Craig Eagle, John Weber and Dr. Joseph Rubinfeld. "The short-term loans extended to us were from people…

WednesdayJun 15, 2011 1:55 pm

Regenicin, Inc. (RGIN) Management Team Focused on Tissue-Engineered Skin Technology

There’s no question that some of the biggest moves in advanced healthcare technology today involve the use of a patient’s own cells, from attacking various diseases to the rebuilding of aged or damaged tissues. In the case of Regenicin, Inc., a New Jersey based biotechnology company, it’s all about the development of regenerative cell therapies to restore the health of damaged tissues. The company is currently working on a breakthrough technology that uses a patient’s own skin cells to generate living tissue-engineered skin for the treatment of burns and wounds. It represents a huge step for the thousands of severe…

ThursdayJun 09, 2011 10:50 am

Regenicin, Inc. (RGIN) Reports Dismissal of Lawsuit

Earlier this morning, Regenicin, Inc. announced it reached an agreement with former company president Mr. Joseph Connell. The parties agreed to dismiss the company and the board of directors which were named in the lawsuit pending in the US District Court for the Southern District of New York. The company in turn has dismissed its action against Mr. Connell. In the press release, the company noted there will be a continued action pending by and between Mr. Connell and Mr. McCoy, the current CEO, but that this dispute is anticipated to be settled. The parties recognize this was a partnership…

WednesdayJun 08, 2011 5:05 pm

Regenicin, Inc. (RGIN) in Advanced Discussions with Developers to Establish New Facilities in Florida

Today shortly before the closing bell, Regenicin, Inc. announces it is in advanced discussions with various developers in the State of Florida to determine the most strategic location and best partners to establish research facilities. Sites presently being considered are world-class research and technology parks, which will allow Regenicin to collaborate with leading centers of excellence in the academic, research, and healthcare arenas. Regenicin is pursuing opportunities to lease new facilities that will not only accommodate the present demands for state-of-the-art lab space, but will also address the projected growth needs the company foresees as it executes its business plan.…

TuesdayJun 07, 2011 10:39 am

Regenicin, Inc. (RGIN) Director Attends the World Stem Cells and Regenerative Medicine Congress 2011

Regenicin, Inc. just announced that Dr. Craig Eagle, who sits on the Regenicin Board of Directors, attended The World Stem Cells and Regenerative Medicine Congress 2011 in an effort to further Regencin's push towards obtaining FDA approval for the commercial sale of its first product candidate. The World Stem Cells and Regenerative Medicine Congress is recognized for offering a senior director-level, interactive conference experience. Speakers and panelists include industry leaders from throughout Europe, North America and Asia. The World Stem Cells and Regenerative Medicine Congress is Europe's most progressive strategic conference where ideas, intelligence and relationships really make a difference.…

MondayJun 06, 2011 4:58 pm

Regenicin, Inc. (RGIN) is “One to Watch”

Regenicin, Inc., headquartered in Little Falls, New Jersey, is a biotechnology company focused on developing regenerative cell therapies to restore the health of damaged tissues and organs. The company has assembled a world-class management team with a proven track record of developing and bringing innovative medical devices and biotechnology products to market. The company is playing a critical role in the development of the therapeutic candidate, PermaDerm™, a breakthrough technology that uses a patient's own skin cells to generate living, tissue-engineered skin for the treatment of severe burns and wounds. Using only a postage-stamp biopsy of the patient's skin, a…

Site Search

Company Search

Tag: Regenicin, Inc. RGIN

Regenicin, Inc. (RGIN) Repays Loans; Continues to Execute Business Strategy

Regenicin, Inc. (RGIN) Management Team Focused on Tissue-Engineered Skin Technology

Regenicin, Inc. (RGIN) Reports Dismissal of Lawsuit

Regenicin, Inc. (RGIN) in Advanced Discussions with Developers to Establish New Facilities in Florida

Regenicin, Inc. (RGIN) Director Attends the World Stem Cells and Regenerative Medicine Congress 2011

Regenicin, Inc. (RGIN) is “One to Watch”

Market Basics

Newsletter Publishers

Public Companies